Gender features of cardiorenal relationships and cytokine status in patients with chronic kidney disease
- Authors: Murkamilov I.T1,2, Aitbaev K.A3, Fomin V.V4
-
Affiliations:
- Kyrgyz State Medical Academy n.a. I.K. Akhunbaev
- Kyrgyz-Russian Slavic University n.a. the First President of the Russian Federation B.N. Yeltsin
- Scientific Research Institute of Molecular Biology and Medicine
- FSBEI he "I.M. Sechenov First Moscow State Medical University''
- Issue: No 2 (2019)
- Pages: 20-26
- Section: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/273189
- DOI: https://doi.org/10.18565/nephrology.2019.2.20-26
- ID: 273189
Cite item
Abstract
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
I. T Murkamilov
Kyrgyz State Medical Academy n.a. I.K. Akhunbaev; Kyrgyz-Russian Slavic University n.a. the First President of the Russian Federation B.N. Yeltsin
Email: murkamilov.i@mail.ru
PhD in Medical Sciences, Nephrologist, Deputy Associate Professor at the Department of Faculty Therapy
K. A Aitbaev
Scientific Research Institute of Molecular Biology and MedicineDoctor of Medical Sciences, Professor, Head of the Laboratory of Pathological Physiology
V. V Fomin
FSBEI he "I.M. Sechenov First Moscow State Medical University''Doctor of Medical Sciences, Professor, Corresponding Member of the Russian Academy of Sciences, Vice-Rector for Clinical Work and Postgraduate Professional Education, Director of the V.N. Vinogradov Faculty Therapy Clinic, Head of the Faculty Therapy Department № 1
References
- Naghavi M, Abajobir A.A., Abbafati C., et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:10100:1151-210. Doi:https://doi.org/10.1016/S0140-6736(17)32152-9.
- Thomas B., Matsushita K., Abate K.H., et al. Global cardiovascular and renal outcomes of reduced GFR. J. Am. Soc. Nephrol. 2017;28:7:2167-2179. Doi: https://doi.org/10.1681/ASN.2016050562.
- Quiroga B., Verdalles U, Reque J., et al. Cardiovascular events and mortality in chronic kidney disease (stages I-IV). Nefrologia (English Edition). 2013;33:4:539-545. doi: 10.3265/Nefrologia.pre2013.Dec.12385.
- Alani H., Tamimi A., Tamimi N. Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs. World J. Nephrol. 2014;3:4:156. doi: 10.5527/wjn.v3.i4.156.
- Cozzolino M., Mangano M., Stucchi A., et al. Cardiovascular disease in dialysis patients. Nephrol. Dial. Transplant. 2018;33(3):28-34. doi: 10.1093/ndt/gfy174.
- Моисеев В.С., Мухин Н.А., Смирнов А.В. и др. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции. Рос. кардиологический журнал. 2014;(8):7-37. Doi:https:// doi.org/10.15829/1560-4071-2014-8-7-37. [Moiseev V.C., Mukhin N.A., Smirnov A.K, et al. Cardiovascular risk and chronic kidney disease: cardio-nephroprotection strategies. Rus. J. Cardiol. 2014;(8):7-37. Doi: https://doi.org/10.15829/1560-4071-2014-8-7-37. (In Russ.)].
- HoekF.J., Kemperman F.A., KredietR.T. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular fi ltration rate. Nephrol. Dial. Transplant. 2003;18(10):2024-31. Doi:10.1093/ ndt/gfg349.
- Lang R.M., Lang R.M., Bierig M., et al. Recommendations for chamber quantification. Eur. J. Echocardiography. 2006;7:2:79-108. Doi:https://doi. org/10.1016/j.euje.2005.12.014.
- Lang R.M., Lang R.M., Badano L.P., et al. Recommendationsfor cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging. 2015;16:3:233-271. Doi:https://doi. org/10.1093/ehjci/jev014.
- Devereux R.B., Alonso D.R., Lutas E.M., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am. J. Cardiol. 1986;57:6:450-8. Doi:https://doi.org/10.1016/0002-9149(86)90771-X
- Williams B., Mancia G., Spiering W., et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur. Heart J. 2018;39:33:3021-104. Doi:https://doi.org/10.1093/eurheartj/ehy339.
- Mancia G., Fagard R., Narkiewicz K., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Pressure. 2013;22:4:193-278. Doi:https://doi. org/10.3109/08037051.2013.812549
- Мухин Н.А., Фомин В.В., Лебедева М.В. Гиперурикемия как компонент кардиоренального синдрома. Тер. архив. 2011;83(6):5-13.
- Кобалава Ж.Д., Виллевальде С.В., Ефремовцева М.А., Моисеев В.С. Кардиоренальные взаимоотношения: современные представления. Кардиоваскулярная терапия и профилактика. 2010;9(4):4-11.
- Moulin B. Cardiorenal syndromes: definition and classification. Rev. Prat. 2016;66(6):608-10. PMID: 27538311.
- Резник Е.В., Никитин И.Г. Кардиоренальный синдром у больных с сердечной недостаточностью как этап кардиоренального континуума (часть I): определение, классификация, патогенез, диагностика, эпидемиология (обзор литературы). Архивъ внутренней медицины. 2019;9(1):5-22. Doi:https://doi.org/10.20514/2226-6704-2019-9-1-5-22 Doi:https://doi. org/10.20514/2226-6704-2019-9-1-5-22
- Takahama H., Kitakaze M. Pathophysiology of cardiorenal syndrome in patients with heart failure: potential therapeutic targets. Am. J. Physiol. Heart Circul. Physiol. 2017;313(4):715-21. Doi:https://doi.org/10.1152/qjpheart.00215.2017
- Di Lullo L., Bellasi A., Barbera V., et al. Pathophysiology of the cardio-renal syndromes types 1-5: An uptodate. Ind. Heart J. 2017;69:2:255-265. Doi:https:// doi.org/10.1016/j.ihj.2017.01.005
- Kingma J., Simard D., Rouleau J., et al. The Physiopathology of Cardiorenal Syndrome: A Review of the Potential Contributions of Inflammation. J. Cardiovasc. Devel. Dis. 2017;4(4):21-23. Doi:https://doi.org/10.3390/jcdd4040021.
- Yan L., Bowman M.A. Chronic sustained inflammation links to left ventricular hypertrophy and aortic valve sclerosis: a new link between S100/RAGE and FGF23. Inflamm. Cell. Signal. 2014;1(5):e279. doi: 10.14800/ics.279.
- Li Z.C., Yu H.Y., Wang X.X., et al. Olmesartan medoxomil reverses left ventricle hypertrophy and reduces inflammatory cytokine IL-6 in the renovascular hypertensive rats. Eur. Rev. Med. Pharmacol. Sci. 2013;17(24):3318-3322.
- Yin J.C., Yin J.C., Platt M.J., et al. Cellular interplay via cytokine hierarchy causes pathological cardiac hypertrophy in RAF1-mutant Noonan syndrome. Nat. Communicat. 2017;8:15518:1-1511. doi: 10.1038/ncomms15518.
- Zafar U., Khaliq S., Ahmad H.U., Lone K.P. Serum profile of cytokines and their genetic variants in metabolic syndrome and healthy subjects: a comparative study. Biosci. Rep. 2019;39(2)BSR20181202. doi: 10.1042/BSR20181202.
- Trifunovic J., Miller L., Debeljak Z., & Horvat V. Pathologic patterns of interleukin 10 expression-a review. Biochem. Med. 2015;25:1:36-48. Doi:https:// doi.org/10.11613/BM.2015.004.
- Конради А.О. Лечение артериальной гипертензии в особых группах больных. Типертрофия левого желудочка. Артериальная гипертензия. 2005;11(2):105- 110.
- Konradi AO. Treatment of hypertension in special groups of patients. Left ventricular hypertrophy. Arterial. Hypertension. 2005;11(2):105-110. (In Russ.)].
- Вебер В.Р., Рубанова М.П., Жмайлова С.В. и др. Ремоделирование левого и правого желудочка сердца при артериальной гипертензии и возможности медикаментозной коррекции. РМЖ. 2009;2:5-9.
- Кобалава Ж.Д., Котовская Ю.В., Сафарова А.Ф. и др. Эхокардиографическая оценка фиброза миокарда у молодых мужчин с артериальной гипертонией и разными типами ремоделирования левого желудочка. Кардиология. 2011;51(2):34-9.
- Душина А.Т., Лопина Е.А., Либис Р.А. Особенности хронической сердечной недостаточности в зависимости от фракции выброса левого желудочка. Рос. кардиол. журнал. 2019;(2):7-11. Doi:https://doi.org/10.15829/1560-4071-2019-2-7-11. Doi:https://doi.org/10.15829/1560-4071-2019-2- 7-11.
- Муркамилов И.Т., Айтбаев К.А., Фомин В.В. Половые особенности сердечнососудистых осложнений у больных хроническим гломерулонефритом на преддиализной стадии заболевания. Тер. архив (архив до 2018 г.). 2017;89:6:56-61. doi: 10.17116/terarkh201789656-61. doi: 10.17116/terarkh201789656-61.
- Муркамилов И.Т., Сабиров И.С., Айтбаев К.А. и др. Почечная дисфункция и показатели артериальной жесткости у лиц пожилого и старческого возраста. Успехи геронтологии. 2018;31:4:549-555.
- Dijk J.M., van der Graat G., Bots M.L., et al. Carotid intima-media thickness and the risk of new vascular events in patients with manifest atherosclerotic disease: the SMART study. Eur. Heart J. 2006; 24:1971-1978. Doi:https://doi.org/10.1093/ eurheartj/ehl136.
- Bots M.L., Hoes A.W., Koudstaal P.J., et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction. The Rotterdam Study. Circulation.1997;96:1432-1437.
- Doi:https://doi.org/10.1161/01.CIR.96.5.1432
- Kablak A., Kablak A., Przewlocki T., et al. Relationship between carotid intima-media thickness, cytokines, atherosclerosis extent and a two-year cardiovascular risk in patients with arteriosclerosis. Kardiol. Polska. (Polish Heart Journal). 2011;69:10:1024-1031.
- Momeni A., Taheri A., Mansuri M., et al. Association of carotid intima-media thickness with exercise tolerance test in type 2 diabetic patients. Int. J. Cardiol. Heart. Vasc. 2018;21:74-77. doi: 10.1016/j.ijcha.2018.10.002.
Supplementary files
![](/img/style/loading.gif)